[1] Chinese Physicians Association Hematologists Branch.Guidelines for the diagnosis and treatment of multiple myeloma in China（revised 2015) ［J］.Chinese Journal of Internal Medicine,2015,54(12):1066-1070.［中国医师协会血液科医师分会.中国多发性骨髓瘤诊治指南(2015年修订)［J］.中华内科杂志,2015,54(12):1066-1070.］
[2] Rajkumar SV,Dimopoulos MA,Palumbo A,et al.International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma［J］.Lancet Oncology,2014,15(12):e538-e548.
[3] LIU Haibo,CHEN Limei.The efficacy of renalidomide combined with low dose dexamethasone in the treatment of multiple myeloma［J］.Chinese Journal of Experimental Hematology,2016,24(2):498-501.［刘海波,陈丽梅.来那度胺联合小剂量地塞米松治疗多发性骨髓瘤的疗效观察［J］.中国实验血液学杂志,2016,24(2):498-501.］
[4] Kumar SK,Callander NS,Alsina M,et al.Multiple myeloma,version 3.2017,NCCN clinical practice guidelines in oncology［J］.J Natl Compr Canc Netw,2017,15(2):230-269.
[5] GU Shanshan,SUN Qi,YANG Wei.Advances in the treatment of multiple myeloma by subcutaneous injection of bortezomil ［J］.Modern Oncology,2016,24(3):505-508.［顾姗姗,孙琪,杨威.皮下注射硼替佐米治疗多发性骨髓瘤研究进展［J］.现代肿瘤医学,2016,24(3):505-508.］
[6] LIN Tong,ZHANG Qiguo,WU Hongyan,et al.Relationship between the expression of NF-κB/p65 in bone marrow of multiple myeloma patients and the efficacy of bortezomil ［J］.Journal of Southeast University（Medical Edition),2016,35(1):41-45.［林桐,张启国,吴鸿雁,等.多发性骨髓瘤患者骨髓组织中NF-κB/p65的表达与硼替佐米疗效的关系［J］.东南大学学报(医学版),2016,35(1):41-45.］
[7] Hideshima T,Anderson KC.Biologic impact of proteasome inhibition in multiple myeloma cells-from the aspects of preclinical studies［J］.Seminars in Hematology,2012,49(3):223-227.
[8] Nunes AT,Annunziata CM.Proteasome inhibitors:Structure and function［J］.Seminars in Oncology,2017,44(6):377-380.
[9] Gandolfi S,Laubach JP,Hideshima T,et al.The proteasome and proteasome inhibitors in multiple myeloma［J］.Cancer Metastasis Rev,2017,36(4):561-584.
[10] Okazuka K.Proteasome inhibitors for multiple myeloma［J］.Japanese Journal of Clinical Oncology,2018,48(9):785-793.
[11] ZHANG Li,LUO Wenda,SHEN Jian,et al.Efficacy and adverse effects of combined chemotherapy with boron tezomil in the treatment of multiple myeloma ［J］.Chinese General Medicine,2016,14(11):1826-1828.［张丽,罗文达,沈健,等.含硼替佐米的联合化疗对多发性骨髓瘤的治疗效果及不良反应［J］.中华全科医学,2016,14(11):1826-1828.］
[12] ZHU Ying,TIAN Chunyan,LIU Shengyan.Efficacy and infection of bortezomil and relidomide combined with dexamethasone in the treatment of multiple myeloma ［J］.Chinese Journal of Nosocomial Infection,2014,24(18):4576-4578.［朱颖,田春燕,刘晟彦.硼替佐米与雷利度胺联合地塞米松治疗多发性骨髓瘤的疗效及感染分析［J］.中华医院感染学杂志,2014,24(18):4576-4578.］
[13] QIN Hui,WANG Yansheng,DING Shihua,et al.Efficacy and safety of subcutaneous bortezomil in the treatment of multiple myeloma ［J］.Journal of Sichuan University（Medical Edition),2014,45(3):529-532.［秦慧,汪延生,丁士华,等.皮下注射硼替佐米治疗多发性骨髓瘤的疗效及安全性分析［J］.四川大学学报(医学版),2014,45(3):529-532.］
[14] LIN Meiying,XIE Youke,YIN Fang,et al.The ccomparison of cost effective of different low dose thalidomide for the elderly patients with multiple myeloma［J］.Journal of Clinical Hematology,2017,30(2):222-224.［林梅英,谢有科,尹芳,等.不同低剂量沙利度胺用于老年人多发性骨髓瘤的临床性价比较［J］.临床血液学杂志,2017,30(2):222-224.］
[15] Liu H,Xu R,Huang H.Peripheral neuropathy outcomes and efficacy of subcutaneous bortezomib when combined with thalidomide and dexamethasone in the treatment of multiple myeloma［J］.Experimental & Therapeutic Medicine,2016,12(5):3041-3046.
[16] Popat R,Brown SR,Flanagan L,et al.Bortezomib,thalidomide,dexamethasone,and panobinostat for patients with relapsed multiple myeloma（MUK-six):A multicentre,open-label,phase 1/2 trial［J］.Lancet Haematology,2016,3(12):e572-e580.
[17] LI Changsheng,JI Ye,ZHANG Wanping,et al.Clinical efficacy and safety of different doses of dexamethasone combined with bortezomib and thalidomide in the treatment of primary multiple myeloma ［J］.Chinese Journal of Experimental Hematology,2018,26(3):836-841.［李长生,冀叶,张莞萍,等.不同剂量地塞米松联合硼替佐米和沙利度胺治疗初发多发性骨髓瘤的临床效果及安全性［J］.中国实验血液学杂志,2018,26(3):836-841.］